Evidence map›Paper›PMID 41887223›Full record

ArticleAmerican journal of human genetics2026

Bi-allelic variants in OLA1 cause a neurodevelopmental disorder with joint hypermobility.

Lama AlAbdi, Abdullah Sezer, Fatema Alzahrani, Sebiha Cevik, Zanyar Demir, Nor Linda Abdullah, Özlem Durukan, Efe Dallı, Mais O Hashem, Omar Abuyousef and 26 more

Abstract read
In one paragraph

Article in American journal of human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

36 authors.

Lama AlAbdiDepartment of Translational Genomics, Genomic Medicine Center of Excellence (GMCoE), King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
Abdullah SezerDepartment of Medical Genetics, Ankara Etlik City Hospital, 06170 Ankara, Türkiye.
Fatema AlzahraniPrecision Medicine Laboratory Department, Genomic Medicine Center of Excellence (GMCoE), King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Sebiha CevikRare Disease Laboratory, School of Life and Natural Sciences, Abdullah Gül University, Kayseri, Türkiye.
Zanyar DemirRare Disease Laboratory, School of Life and Natural Sciences, Abdullah Gül University, Kayseri, Türkiye.
Nor Linda AbdullahBiomedical Science Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of Saudi Arabia.
Özlem Durukanİntergen Genetics and Rare Disease Diagnosis Center, R&D Department, Ankara, Türkiye.
Efe Dallıİntergen Genetics and Rare Disease Diagnosis Center, R&D Department, Ankara, Türkiye.
Mais O HashemDepartment of Translational Genomics, Genomic Medicine Center of Excellence (GMCoE), King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
Omar AbuyousefDepartment of Translational Genomics, Genomic Medicine Center of Excellence (GMCoE), King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
Bayan AljamalDepartment of Translational Genomics, Genomic Medicine Center of Excellence (GMCoE), King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
Rana HelabyDepartment of Translational Genomics, Genomic Medicine Center of Excellence (GMCoE), King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
Mona RadwanDepartment of Translational Genomics, Genomic Medicine Center of Excellence (GMCoE), King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
Amal JaafarDepartment of Translational Genomics, Genomic Medicine Center of Excellence (GMCoE), King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
Tarfa AlshidiDepartment of Translational Genomics, Genomic Medicine Center of Excellence (GMCoE), King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia.
Israa SalemKAUST Center for Smart Health, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of Saudi Arabia.
Halima HamidLifera Omics, Riyadh 13519, Saudi Arabia.
Bader AlhaddadLifera Omics, Riyadh 13519, Saudi Arabia.
Khadijah BakurLifera Omics, Riyadh 13519, Saudi Arabia.
Elifcan TaşdelenDepartment of Medical Genetics, Ankara Etlik City Hospital, 06170 Ankara, Türkiye.
Mustafa KılıçDepartment of Pediatric Metabolism, Ankara Etlik City Hospital, 06170 Ankara, Türkiye.
Mohammed Al-OwainMedical Genomics Department, Genomic Medicine Center of Excellence (GMCoE), King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.
Amal AlhashemCollege of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia; Seha Virtual Hospital, Ministry of Health, Riyadh 12382, Saudi Arabia; Department of Genetics and Metabolics, King Fahad Specialist Hospital, Dammam 32253, Saudi Arabia.
Eirik BratlandDepartment of Medical Genetics, Haukeland University Hospital, 5009 Bergen, Norway.
Julie PaulsenDepartment of Medical Genetics, Haukeland University Hospital, 5009 Bergen, Norway; Department of Medical Genetics, St. Olavs Hospital, Trondheim University Hospital, 7006 Trondheim, Norway.
Gunnar Houge DouzgosDepartment of Medical Genetics, Haukeland University Hospital, 5009 Bergen, Norway.
Anya Revah PolitiPrecision Genomics Laboratory, Institute for Genomic Medicine, Columbia University Medical Center, New York, NY 10032, USA.
Kevin UguenService de Génétique Médicale et Biologie de la Reproduction, CHRU de Brest, Brest, France; University Brest, INSERM, EFS, UMR 1078, GGB, 29200 Brest, France; Centre de Référence Déficiences Intellectuelles, Service de Pédiatrie, CHU de Brest, Brest, France.
Emmanuelle MassonService de Génétique Médicale et Biologie de la Reproduction, CHRU de Brest, Brest, France; University Brest, INSERM, EFS, UMR 1078, GGB, 29200 Brest, France.
Severine AudebertService de Génétique Médicale et Biologie de la Reproduction, CHRU de Brest, Brest, France; Centre de Référence Déficiences Intellectuelles, Service de Pédiatrie, CHU de Brest, Brest, France.
Talal AlAnziWomen and Children's Health Department Johns Hopkins Aramco Healthcare Center, Dhahran, Saudi Arabia.
Stefan T AroldBiomedical Science Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of Saudi Arabia.
Bora Erginİntergen Genetics and Rare Disease Diagnosis Center, R&D Department, Ankara, Türkiye.
Leena A IbrahimBiomedical Science Division, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of Saudi Arabia; KAUST Center for Smart Health, King Abdullah University of Science and Technology (KAUST), Thuwal 23955-6900, Kingdom of Saudi Arabia.
Oktay I KaplanRare Disease Laboratory, School of Life and Natural Sciences, Abdullah Gül University, Kayseri, Türkiye. Electronic address: oktaykaplan@gmail.com.
Fowzan S AlkurayaDepartment of Translational Genomics, Genomic Medicine Center of Excellence (GMCoE), King Faisal Specialist Hospital and Research Center, Riyadh 11211, Saudi Arabia; Lifera Omics, Riyadh 13519, Saudi Arabia; College of Medicine, Alfaisal University, Riyadh 11533, Saudi Arabia. Electronic address: falkuraya@liferaomics.sa.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cytoskeletal organization, cell adhesion, and cell motility are key to neuronal development and functional synapses. Obg-like ATPase 1 (OLA1) regulates cell-matrix adhesion by modulating focal adhesion kinase (FAK) levels, therefore regulating cytoskeletal dynamics and cell motility. To date, however, no Mendelian phenotypes in humans have been linked to OLA1. We identified fourteen individuals from nine families in whom hypermobility-neurodevelopmental disorder with distinct facies is linked to bi-allelic deleterious variants in OLA1. The hypermobility phenotype evoked a diagnosis of Ehlers-Danlos syndrome (EDS) in some affected individuals. The loss-of-function nature of these variants is confirmed in proband-derived fibroblasts, recapitulating the impaired migration and proliferation phenotype previously described in OLA1-deficient cells. To explore the pathogenesis of abnormal neurodevelopment in our probands, we investigated neurons derived from proband fibroblasts and identified impaired adhesion and cytoskeletal control. Modeling ola-1 deficiency in C. elegans revealed reduced neurite numbers compared to the wild type. Additionally, transcriptomic analysis of the ola-1-deficient worms suggested that dysregulation of key signaling pathways results in suppression of microtubule dynamics and axon regrowth, ultimately crippling the regenerative competence of mutant animals compared to wild-type controls. Our results support an autosomal-recessive OLA1-related hypermobility-neurodevelopmental disorder and suggest that dysregulation of key signaling pathways results in the suppression of microtubule dynamics as a potential underlying mechanism.

Indexed as

Ehlers-Danlos SyndromeJoint InstabilityNeurodevelopmental DisordersAllelesAnimalsCaenorhabditis elegansCell AdhesionCell MovementChildChild, PreschoolFemaleFibroblastsHumansMaleNeuronsPedigreeC. eleganscell adhesionjoint hypermobilityOLA1RNA-seq

Identifiers

PMID41887223
PMCPMC13087460

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.